Dyslipidemia Market is anticipated to surge due to an increasingly prevalent population of Dyslipidemia, the expected launch of emerging drugs, increasing global geriatric population, increase in the prevalence of lifestyle-related (obesity) and cardiovascular disorders, as well as entry of many key pharmaceuticals such as Kowa, Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, and others in the Dyslipidemia Market.
DelveInsight’s Dyslipidemia Market Insights report proffers a detailed comprehension of Dyslipidemia market size by treatment, epidemiology, emerging therapies, Dyslipidemia market share of the individual therapies, current and forecasted Dyslipidemia market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the salient features from the Dyslipidemia Market Report:
- DelveInsight’s analysts estimate that the Dyslipidemia market is expected to show positive growth, mainly attributed to the increase in the prevalence of Dyslipidemia and the anticipated launch of novel therapies during the forecast period.
- Key pharmaceutical companies in the Dyslipidemia market such as Kowa, Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, EMS under NC Farma, among other Dyslipidemia companies are proactively working to change the dynamics of the market.
- The Dyslipidemia pipeline therapies include Pemafibrate (K-877), Parexel, ARO-ANG3, Gemcabene, Vupanorsen (formerly known as AKCEA-ANGPTL3-LRx), AZD8233, LY3475766, Cipros 10 association, and others that are expected to launch in the study period 2019-32.
- According to DelveInsight analysis, the increase in Dyslipidemia market size is a direct outcome related to the increasingly prevalent population of Dyslipidemia, and the expected launch of emerging drugs in the 7MM, along with great competition among various companies and precision approach that will lead to the more effective therapies.
- The available therapeutics treatment options in the Dyslipidemia treatment landscape aim to provide a cure to the patients suffering from this indication, however, there are several challenges that are yet to be tackled.
For further information on Market Impact by Therapies, Download Dyslipidemia sample @ Dyslipidemia Market Report
Dyslipidemia is a condition caused by the abnormal fluctuation in the levels of cholesterol level as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL) leading to heart disease. Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue. Dyslipidemia is segmented into two major types on the basis of their causes known as Primary Dyslipidemia and Secondary Dyslipidemia.
Dyslipidemia is known to promote atherosclerosis. It is a complex disease and is a high-risk factor for adverse cardiovascular diseases. Dyslipidemia treatment varies depending on the severity. Initial medications such as statins are recommended as first-line treatment of severe dyslipidemia, along with lifestyle changes including exercise, diet control, maintaining a healthy body weight are also suggested in order to have an effective hold on the disease.
The most prevalent Dyslipidemia type was found to be Hypercholesterolemia. The prevalence of Dyslipidemia in various regions differed in climate, geographic, economic, and ethnic characteristics. The Dyslipidemia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into-
- Total Prevalent Cases of Dyslipidemia
- Total Diagnosed Cases of Dyslipidemia
- Age-Specific Cases of Dyslipidemia
- Gender-Specific Cases of Dyslipidemia
- Treated Cases of Dyslipidemia
Know-how Dyslipidemia Epidemiological Trends are going to look like in 2032 for the 7 MM by downloading @ Dyslipidemia Epidemiological Insights
There are a variety of Dyslipidemia treatments and other measures available to address the disease. Hypolipidemias are not treated unless they are severe, usually in some cases where the condition is inherited.
Dyslipidemia prevention, as well as Dyslipidemia treatment, should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, ezetimibe, fibrates (fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil), and nicotinic acid (niacin, also called vitamin B3, PP) represent the second-choice drugs. In addition, anti-PCSK9 drugs (evolocumab, alirocumab, and inclisiran) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Another class of drugs includes bile acid-binding resins (including cholestyramine, colesevelam, and colestipol) are orally administered anion-exchange resins that are neither absorbed systemically nor metabolized by digestive enzymes.
A robust pipeline in the Dyslipidemia treatment landscape is indicative of the very high market potential of Dyslipidemia drugs, this includes pipeline drugs like Pemafibrate (K-877) is being developed by the Kowa Company is a selective Peroxisome Proliferator-Activated Receptors (PPARs) modulator. Pemafibrate is currently undergoing Phase III (NCT04716595) trial to assess its ability to improve patients’ health. AstraZeneca in collaboration with Parexel is developing AZD8233 which is currently in Phase II of clinical trials. Another major anticipated Dyslipidemia drug in the pipeline is ARO-ANG3, it is an investigational agent from Arrowhead Pharmaceuticals, it belongs to the class of Antihyperlipidemic which is in Phase II (NCT04832971) developmental stage. Also, Eli Lilly and Company’s investigational candidate for Dyslipidemia is LY3475766 which is currently in Phase I stage of clinical trials.
Discover more about therapy set to grab substantial Dyslipidemia market share @ Dyslipidemia Therapeutic Landscape
- Pemafibrate (K-877): Kowa Company
- ARO-ANG3: Arrowhead Pharmaceuticals
- Vupanorsen: Pfizer
- Gemcabene: NeuroBo Pharmaceuticals
- AZD8233: AstraZeneca
- LY3475766: Eli Lilly and Company
- Cipros 10 association: EMS under NC Farma
To know about more Global Dyslipidemia drugs market and pipeline therapies under different development phases visit @ Dyslipidemia Pipeline Assessment and Emerging Therapies
A robust pipeline of novel and emerging therapies, increasing global geriatric population, increase in the prevalence of lifestyle-related (obesity) and cardiovascular disorders serve as major aspects for Dyslipidemia market growth in the upcoming years. The increase in the Dyslipidemia market is a direct outcome related to the increasing Dyslipidemia prevalent population and the anticipated launch of emerging Dyslipidemia drugs in the coming years.
On the contrary, in the unreported and undiagnosed Dyslipidemia cases, a significant proportion of treated patients do not reach the recommended treatment goal and an increase in the availability of generic drugs can be considered some of the potential drawbacks of the Dyslipidemia market.
Know more about which MedTech player is set to emerge as the trendsetter @ Dyslipidemia Companies Analysis
Scope of the Dyslipidemia Report
- Study Period: 2019-32
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Dyslipidemia Companies: Kowa, Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, EMS under NC Farma
- Key Dyslipidemia Pipeline Therapies: Pemafibrate (K-877), Parexel, ARO-ANG3, Gemcabene, Vupanorsen (formerly known as AKCEA-ANGPTL3-LRx), AZD8233, LY3475766, Cipros 10 association
- Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and emerging therapies
- Dyslipidemia Market Dynamics: Dyslipidemia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
Table of Contents
|2||Executive Summary of Dyslipidemia|
|3||SWOT Analysis of Dyslipidemia|
|4||Dyslipidemia: Market Share (%) Distribution Overview at a Glance: By Country|
|5||Dyslipidemia Epidemiology and Market Methodology|
|6||Dyslipidemia: Disease Background and Overview|
|7||Dyslipidemia Epidemiology and Patient Population|
|8||Dyslipidemia Epidemiology Scenario: 7MM|
|9||The United States Epidemiology in Dyslipidemia|
|10||EU-5 Epidemiology in Dyslipidemia|
|11||Japan Epidemiology in Dyslipidemia|
|12||Current Treatment Practices of Dyslipidemia|
|13||Unmet Needs in Dyslipidemia|
|14||Patient Journey of Dyslipidemia|
|15||Key Endpoints in Dyslipidemia Clinical Trials|
|16||Marketed Therapies in Dyslipidemia|
|17||Emerging Therapies in Dyslipidemia pipeline|
|17.1||Pemafibrate (K-877): Kowa Company|
|17.2||LY3475766: Eli Lilly and Company|
|18||Conjoint Analysis of Dyslipidemia|
|19||Dyslipidemia: Seven Major Market Analysis|
|20||7MM Market Size|
|21||United States Market Size|
|22||EU-5 Market Size|
|23||Japan Market Size|
|24||Dyslipidemia Market Access and Reimbursement of Dyslipidemia Therapies|
|25||Dyslipidemia Market Drivers|
|26||Dyslipidemia Market Barriers|
Get in touch with our Business executive @ Dyslipidemia Market Landscape Analysis
“Dyslipidemia Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dyslipidemia market. A detailed picture of the Dyslipidemia pipeline landscape is provided, which includes the disease overview, treatment guidelines, Dyslipidemia pipeline products, and key Dyslipidemia companies involved such as Pfizer, Kowa, Eli Lilly and Company, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, and others.
DelveInsight’s ‘Dyslipidemia AEpidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Dyslipidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
“Cholesteryl ester Transfer Protein (CETP) Inhibitor – Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cholesterylester Transfer Protein (CETP) Inhibitor pipeline landscape is provided. In the report, a detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition.
“Cholesterol Absorption Inhibitor – Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cholesterol Absorption Inhibitor pipeline landscape is provided. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers, and acquisition, funding, designations, and other product-related details.
The global Wound Closure Devices market was valued at USD 14.82 billion in 2020, growing at a CAGR of 7.40% during the forecast period from 2021 to 2026, to reach USD 22.64 billion by 2026. The report deliver an in-depth understanding of the Wound Closure Devices, historical and forecasted epidemiology, as well as the Wound Closure Devices market trends, market drivers & barriers, unmet needs and key Wound Closure Devices companies, involved such as Johnson & Johnson, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Healthium Medtech, Meril Life Sciences, Futura Surgicare Pvt Ltd, Advanced Medical Solutions Group plc, Microcure (Suzhou) Medical Technology Co., Ltd, CooperSurgical Inc, Adhezion Biomedical, and several others.
The global Hearing Aid Devices market was valued at USD 6.69 billion in 2020, growing at a CAGR of 5.45% during the forecast period from 2021 to 2026, to reach USD 9.20 billion by 2026. The report delivers an in-depth understanding of the Hearing Aid Devices, historical and forecasted epidemiology as well as the Hearing Aid Devices market trends, market drivers & barriers, unmet needs, and key Hearing Aid Devices companies involved such as Amplifon, Audina Hearing Instruments, Sonova, Demant A/S, Arphi Electronics Private Limited, Foshan Vohom Technology Co., RION Co., Eargo Inc, Elkon Pvt Ltd, Starkey Laboratories, WS Audiology Denmark A/S, Horentek Hearing Diagnostics, Bernafon, and others.
Browse Through Our Blog Posts
- Epidemiology: Fatty Liver Disease
- Cholesterol drug Praluent successful in reducing heart risk
- Analyzing the Key Opportunities & Challenges in the Nutraceuticals Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.